ABSTRACT
Experimental studies in laboratory animals showed reserpine in doses of 0.01-0.05 mg/kg body weight to inhibit the development of rabies infection in white mice and rabbits by 40.0-83.4% depending on the dose and mode of administration. The inhibiting properties of reserpine were demonstrated for both fixed and street rabies virus strains. The protective effect of the drug was manifested after parenteral and oral administration to the infected animals. The experimental data suggest that reserpine may be used as an antiviral drug for protective treatment of rabies in the incubation period.
Subject(s)
Rabies/drug therapy , Reserpine/administration & dosage , Administration, Oral , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Injections, Intramuscular , Mice , Rabbits , Rabies/mortality , Time FactorsABSTRACT
The experiments showed that in a dose of 35-70 mg/kg rifampicin inhibited reproduction of the fixed rabies virus in the brain of infected animals. The drug had no inhibitory effect on synthesis of the virus-neutralizing antibodies after vaccination. Combination of rifampicin with antirabies gamma-globulin had a marked synergistic effect. The animal survival after the combination use amounted to 75-100 per cent and depended on the infective dose of the virus and the scheme of the drug administration. It was concluded that rifampicin might be used in complex therapy of rabies during the incubation period (along with gamma-globulin and the vaccine) for inhibiting virus reproduction at early infection stages.
Subject(s)
Disease Models, Animal , Immunization, Passive , Rabies/therapy , Rifampin/administration & dosage , gamma-Globulins/administration & dosage , Adjuvants, Immunologic , Animals , Antibodies, Viral/biosynthesis , Antiviral Agents , Drug Therapy, Combination , Mice , Rabies/immunology , Rabies/microbiology , Rabies virus/drug effects , Rabies virus/immunology , Rabies virus/physiology , Virus Replication/drug effects , Virus Replication/physiologySubject(s)
Antiviral Agents , Lincomycin/therapeutic use , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Encephalitis Viruses/drug effects , Encephalitis Viruses/physiology , Encephalitis, Arbovirus/drug therapy , Encephalitis, Arbovirus/mortality , Encephalomyelitis/drug therapy , Encephalomyelitis/mortality , Mice , Vero Cells , Virus Replication/drug effectsSubject(s)
Encephalitis, Tick-Borne/prevention & control , Encephalomyelitis, Equine/prevention & control , Encephalomyelitis, Venezuelan Equine/prevention & control , Encephalomyelitis/prevention & control , Methisazone/therapeutic use , Rabies/prevention & control , Thiosemicarbazones/therapeutic use , Animals , Drug Evaluation, Preclinical , Encephalitis Virus, Eastern Equine , Encephalitis, Tick-Borne/mortality , Encephalomyelitis/mortality , Encephalomyelitis, Equine/mortality , Encephalomyelitis, Venezuelan Equine/mortality , Mice , Time FactorsABSTRACT
The paper presents the results of the experimental study of the action of rifampicin on the process of rabies infection in albino mice contaminated with 1-10 LD50 of the fixed rabies virus. Exposure to rifampicin in doses of 250 and 500 micrograms/mouse (35-70 mg/kg) resulted in survival of 66.7 and 83.4 per cent of the animals respectively while in the controls it did not exceed 16.6 and 25.0 per cent. The average life-span of the albino mice treated with the antibiotic increased 1.6-2.4-fold in comparison with the controls. The chemotherapeutic index of rifampicin representing the ratio of the maximum tolerance dose to the minimum dose providing the protective action was equal to 20. The protective action was observed either after administration of the antibiotic according to the treatment-and-prophylaxis scheme or after administration of its 2- or 3-fold dose once a day immediately after the contamination.
